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Background
Combined inhibition of BRAF and MEK is hypothesized
to improve clinical outcomes by preventing or delaying
onset of resistance observed with BRAF inhibitors alone.
This randomized phase 3 study evaluated the combina-
tion of the BRAF inhibitor vemurafenib and the MEK
inhibitor cobimetinib.
Materials and methods
495 patients were randomly assigned to receive vemura-
fenib + cobimetinib (60 mg QD, 21 days on/7 days off)
or vemurafenib (960 mg BID) + placebo. Eligibility
included treatment-naive BRAFV600 mutation–positive
patients with unresectable locally advanced or metastatic
melanoma and adequate performance status and organ
function. The primary end point was investigator-
assessed progression-free survival (PFS). Safety monitor-
ing included serial cardiac and ophthalmic evaluation
and measurement of creatine phosphokinase.
Results
Median PFS was 9.9 months with the combination com-
pared with 6.2 months with the control (HR, 0.51; 95%
CI, 0.39-0.68; P<0.0001). Objective response rate (ORR)
was 68% in the combination and 45% in the control arm
(P<0.0001), including complete response in 10% in the
combination and 4% of patients in the control group.
Subgroup analyses of PFS based on key demographic and
tumor characteristics were consistent with PFS in the
intent-to-treat population, including those with normal
or elevated baseline lactate dehydrogenase (LDH). PFS
assessed by independent review was comparable with
investigator-assessed PFS. Interim overall survival (OS)
data showed an HR of 0.65 (95% CI, 0.42-1.00) but did
not cross the prespecified stopping boundary. Compared
with vemurafenib alone, the combination was associated
with a higher incidence of grade 3 or 4 adverse events
(65% vs 59%), with no difference in the rate of adverse
events leading to study drug discontinuation (13% vs
12%). Most grade ≥3 events occurred in the first 28 days
and resolved quickly. Known MEK inhibitor–related toxi-
cities such as diarrhea, serous retinopathy, elevated crea-
tine phosphokinase, and increased liver transaminase
levels were more commonly observed with the combina-
tion. The majority was grade 1 or 2, occurred between 1
and 4 months in the treatment course, and resolved
quickly. The occurrence of secondary cutaneous neo-
plasms decreased with the combination (4% vs 18%).
Photosensitivity was more common in patients treated
with the combination (all grades 32% vs 18%).1Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy
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Conclusion
Cobimetinib + vemurafenib significantly improved PFS
and response rate among patients with BRAFV600-mutant
metastatic melanoma, with promising preliminary OS ana-
lysis. Most combination-related toxicities are mild or mod-
erate, occur early in treatment, and are manageable by
dose modification and supportive care; treatment disconti-
nuation is uncommon.
Clinical trial registration number
NCT01689519.
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